1. INTRODUCTION {#sec1}
===============

With the advances in the treatment of many cancers, patient survival has improved dramatically such that a second malignant neoplasm is now observed more frequently \[[@B1], [@B2]\]. It is well known that certain cancers are associated with an increased risk of a second cancer \[[@B3], [@B4]\], and that some treatments for cancer are in themselves known to be aetiological agents in the pathogenesis of a second cancer \[[@B5], [@B6]\] . It is commonly assumed that bone lesions occurring in patients who have already had a malignant neoplasm are metastases from that malignancy. If the lesions are multiple, this will almost always be true, but if the lesion is solitary then further investigation is necessary to exclude other pathologies such as another primary bone tumour.

2. MATERIALS AND METHODS {#sec2}
========================

The patients for this study were identified from a prospectively recorded database. The records of 60 patients who presented to our institution between 1980 and 2001 with a primary bone tumour following a prior malignancy were reviewed. The data was analysed in three separate groups, although it should be pointed out that certain patients might belong to more than one group.

Patients were categorised into this group if they had a primary malignant neoplasm that is known to have a strong relationship with the development of a secondary malignancy.

This group included patients who had treatment of their primary tumour that is known to predispose to the development of secondary sarcoma. This includes all the radiation-induced sarcomas that arose within the radiation field.

Patients who developed a primary tumour of bone, subsequent to a different primary malignant neoplasm that was not clearly related to that neoplasm or to the treatment used for that neoplasm, were included in this group.

3. RESULTS {#sec3}
==========

At latest follow up, 31 patients (52%) within the study group had died of disease relating to the primary bone sarcoma. The average time to development of metastases was 17.6 months (range 0--122 months).

This group consisted of three patients (5%), all of whom had retinoblastoma as their first tumour. The sarcoma that subsequently developed was an osteosarcoma in two and a primary leiomyosarcoma of bone in the other. The ages at which the second tumour arose were ten, sixteen, and twenty three years, with a lag time from the original tumour of eight, fifteen, and twenty two years, respectively. All the second tumours were located in sites remote from the head and neck.

There were twenty four patients (40%) who developed a sarcoma following previous radiotherapy for a primary tumour. Of these, twenty two were osteosarcoma and two were high-grade sarcoma with no identifiable differentiation. All of these secondary tumours were located in the previous radiation field. The average age of the patients at time of diagnosis of the second tumour was 45 years (range 16--80 years) with a lag time from the initial tumour of 14 years (range 4--31 years).

Thirty three patients (55%) developed a primary malignant bone tumour following a previous malignancy that was not felt to be clearly related to or associated with the treatment of the first malignancy ([Table 1](#tab1){ref-type="table"}). The average age at diagnosis of the second malignancy was 52 years (range 8--84 years) and the lag time between tumours was 5 years (range 0--18 years). The most common initial malignancy was carcinoma of the breast (thirteen patients), which was associated with chondrosarcoma in six cases. Three patients presenting with breast cancer developed bone sarcomas in the proximal limb girdle. Only one of these patients received radiotherapy as treatment for their breast cancer. The bone sarcoma in this patient occurred in the contralateral proximal humerus. Chondrosarcoma was the most common second malignancy, affecting twelve patients. The tumours occurred at a wide distribution of sites, most frequently in the proximal femur (eight patients). Three of the 33 patients presented with a soft tissue sarcoma as the initial malignancy. The subsequent primary bone tumours were located in sites remote from the initial sarcoma and were felt to have histology unrelated to the initial tumour.

4. DISCUSSION {#sec4}
=============

Significant progress has been made in the treatment of and survival from numerous malignant neoplasms in recent years. The improvement in patient survival has revealed previously unrecognised sequelae. The second malignant neoplasm is a well-described entity \[[@B1], [@B2]\]. It is becoming clearer that genetic factors play a major role in the aetiology of the second malignant neoplasm. These factors are already well established in patients with tumours such as retinoblastoma and Ewings sarcoma \[[@B4], [@B7]\]. In this study, we have reported six cases of breast carcinoma associated with chondrosarcoma. Recently, this association has been reported by others and a genetic trait postulated \[[@B8]\]. It has also been observed that cancer patients themselves are at greater risk of developing a subsequent malignancy than the general population \[[@B1]\].

Treatments for cancer have also been implicated in the aetiology of a second malignant neoplasm. Radiotherapy is a well-established causative agent and is dose dependent \[[@B6]\]. More recently, certain chemotherapeutic agents have also been implicated \[[@B9]\].

There is a tendency to assume that a solitary bone lesion following a malignancy is a metastasis from that malignancy. This is especially true if the patient is over 40 \[[@B10]\] , and the interval between the initial malignancy and the second presentation is short. It was unfortunately beyond the capability of this study to provide a denominator of the number of patients with metastatic solitary bone lesions from the same population that presented to our tertiary referral centre with second and different primary bone tumours.

It is sobering to see that for the Group 3, patients in this study the average interval between tumours was only five years, and the average age of the patients was 52 years. In patients who have had radiotherapy to a previous lesion (Group 2), the assumption that the subsequent bone lesion is recurrent disease from the first malignancy can result in incorrect or substandard therapy.

The potential deleterious effects of a poorly performed biopsy have been well described by Mankin et al. \[[@B11]\] . There are now several reports illustrating the disastrous effects of inappropriate treatment of primary bone sarcomas, usually brought about by the assumption that the lesion is a metastasis \[[@B12]\]. In this study, patients managed in our tertiary referral centre had a biopsy prior to initial treatment. However, we know of at least 3 cases where presumption of the diagnosis of metastasis led to substandard treatment. This was caused by the assumption that the lesion was a metastasis, and the failure by the general orthopaedic surgeon to maintain an index of suspicion that a solitary bone lesion could be a primary bone sarcoma. Whist no particular traits were established, lesions in atypical sites (e.g., scapula, fibula) should be regarded with extrasuspicion. Most of the lesions in this study had characteristic appearances of primary bone sarcomas rather than metastases.

Internal fixation of these lesions can spread tumour cells along the whole length of the bone, rendering limb salvage surgery impossible. Clearly, therefore, we would urge caution in the treatment of solitary bone lesions, even in the presence of previous malignancy. There is rarely error in temporarily delaying potentially deleterious surgery or radiotherapy, imaging the patient appropriately, and performing a biopsy by a surgeon experienced in orthopaedic oncological procedure \[[@B13]\].

###### 

Data for the Group 3 patients, in whom there was no clearly defined association between malignancies.

  Patient   Age (at diagnosis of second tumour)yrs   Sex   Second tumour (primary bone sarcoma)   Initial malignancy (Ca: carcinoma)              Site of second tumour   Lag (time to second tumour)yrs
  --------- ---------------------------------------- ----- -------------------------------------- ----------------------------------------------- ----------------------- --------------------------------
  1         72                                       F     Chondrosarcoma                         Ca breast                                       Prox femur              14
  2         59                                       F     Chondrosarcoma                         Ca breast                                       Prox humerus            1
  3         50                                       F     Chondrosarcoma                         Ca breast                                       Prox femur              16
  4         58                                       F     Chondrosarcoma                         Ca breast                                       Prox humerus            2
  5         60                                       F     Chondrosarcoma                         Ca breast                                       Distal femur            0
  6         60                                       F     Chondrosarcoma                         Ca bronchus                                     Prox tibia              2
  7         72                                       F     Chondrosarcoma                         Ca colon                                        Distal femur            4
  8         44                                       M     Chondrosarcoma                         Ca oesophagus                                   Pelvis                  6
  9         58                                       M     Chondrosarcoma                         Ca rectum                                       Prox tibia              7
  10        82                                       M     Chondrosarcoma                         Leukaemia                                       Prox femur              6
  11        52                                       F     Chondrosarcoma                         Malignant melanoma                              Pelvis                  3
  12        66                                       F     Chondrosarcoma                         Ca breast                                       Metatarsal              0
  13        66                                       F     Chordoma                               Ca breast                                       Sacrum                  0
  14        55                                       F     Chordoma                               Ca breast                                       Sacrum                  12
  15        29                                       F     Ewings sarcoma                         Ca kidney                                       Prox femur              0
  16        12                                       F     Ewings sarcoma                         Hodgkin\'s lymphoma                             Fibula                  6
  17        9                                        M     Ewings sarcoma                         Leukaemia                                       Prox tibia              5
  18        78                                       M     Fibrosarcoma                           Malignant fibrous histiocytoma (soft tisssue)   Pelvis                  2
  19        41                                       F     Fibrosarcoma                           Malignant melanoma                              Prox femur              3
  20        84                                       F     Leiomyosarcoma                         Ca breast                                       Distal fibula           8
  21        47                                       F     Malignant fibrous histiocytoma         Hodgkin\'s lymphoma                             Distal femur            6
  22        39                                       M     Malignant fibrous histiocytoma         Seminoma                                        Distal femur            10
  23        27                                       F     Malignant fibrous histiocytoma         Ca breast                                       Prox femur              2
  24        66                                       M     Osteosarcoma                           Ca bladder                                      Scapula                 3
  25        63                                       F     Osteosarcoma                           Ca breast                                       Prox femur              5
  26        10                                       M     Osteosarcoma                           Hodgkin\'s lymphoma                             Prox humerus            3
  27        33                                       F     Osteosarcoma                           Malignant melanoma                              Prox tibia              4
  28        8                                        F     Osteosarcoma                           Rhabdomyosarcoma                                Prox tibia              5
  29        12                                       M     Osteosarcoma                           Rhabdomyosarcoma                                Prox femur              11
  30        81                                       F     Sarcoma                                Ca breast                                       Prox fibula             0
  31        72                                       F     Sarcoma                                Ca breast                                       Scapula                 3
  32        69                                       M     Spindle cell sarcoma                   Ca prostate                                     Scapula                 1
  33        81                                       F     Spindle cell sarcoma                   Ca colon                                        Prox tibia              18
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